Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 31:12:835320.
doi: 10.3389/fonc.2022.835320. eCollection 2022.

The Impact of Statin Use and Breast Cancer Recurrence - A Retrospective Study in Singapore

Yirong Sim  1   2   3 , Cindy Lim  4 , Nitar Phyu  5 , Kiat Tee Benita Tan  1   2   3   6 , Lita Sui Tjien Chew  7 , Chow Yin Wong  2   3 , Preetha Madhukumar  1   2   3 , Wei Sean Yong  1   2   3 , Sue Zann Lim  1   2   3 , Julie Liana Bte Hamzah  1   2   3 , Si Ying Tan  1   2   3 , Wen Yee Chay  8 , Fuh Yong Wong  9 , Puay Hoon Tan  10 , Veronique Kiak-Mien Tan  1   2   3
Affiliations

The Impact of Statin Use and Breast Cancer Recurrence - A Retrospective Study in Singapore

Yirong Sim et al. Front Oncol. .

Abstract

Introduction: Statins, HMG-CoA reductase inhibitors, are commonly used cholesterol-lowering medications which are also increasingly recognized to have anti-cancer properties for various cancers, including breast cancer. Most clinical evidence supports a protective effect of statin on reducing breast cancer recurrence, particularly in hormone-receptor positive breast cancers.This study seeks to study the impact of statin use on breast cancer recurrence in an Asian population.

Methods: This is a retrospective study of patients diagnosed with breast cancer at the National Cancer Centre and Singapore General Hospital from 2005-2015. Statin use was defined as use after surgery. Associations between statin use, breast cancer recurrence and overall survival were estimated using Cox proportional hazards regression with adjustment for age, TNM stage, grade, ER/HER2 status, and co-morbidities. Associations between statin-use and disease-specific survival were estimated using competing risks regression.

Results: A total of 7858 females with breast cancer were studied, 1353(17.2%) were statin users, 6505(82.8%) were non-statin users, with a median follow-up of 8.67 years. Distribution of cancer stage, histology, molecular subtypes and grades were similar in both groups. Estrogen receptor(ER) positive (HR 0.57,95%CI 0.43-0.76,p<0.001) and HER2 negative (HR 0.74,95%CI 0.57-0.96,p=0.026) invasive cancers had a lower risk of recurrence in statin users. Statin users trended towards a long term recurrence-risk reduction (all subtypes,HR 0.48,p=0.002; ER-, HR 0.34,p=0.036; HER2+,HR 0.10,p=0.002). The risk-reduction benefit is not appreciated in statin users with DCIS, possibly due to small recurrence event numbers. Disease-specific survival benefit was seen in statin users with ER+ cancers (adjusted SHR 0.71,95%CI 0.53-0.96,p=0.027), especially ER+ invasive cancers (adjusted SHR 0.72, 95%CI 0.53-0.97,p=0.028), but with no statistically significant benefit in overall survival for statin users (all subtypes).

Conclusion: This is the first known retrospective study on the effect of statin use and breast cancer recurrence in an Asian population. Similar to previous international studies, statin use is associated with a risk reduction in breast cancer recurrence. This is especially beneficial in patients who have ER+ and HER2- invasive breast cancer. Statin use is also associated with a reduced risk of breast cancer recurrence in all subtypes of breast cancer in the long term (>6 years post diagnosis).

Keywords: Asia; HMG-CoA reductase inhibitor; breast cancer; recurrence; statin.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
CONSOT Diagram to summarize the number of patients included and excluded in this study. NCCS, National Cancer Centre Singapore; SGH, Singapore General Hospital; TNM, Tumor Nodal Metastasis staging.
See this image and copyright information in PMC

References

    1. Dunnwald LK, Rossing MA, Li CI. Hormone Receptor Status, Tumor Characteristics, and Prognosis: A Prospective Cohort of Breast Cancer Patients. Breast Cancer Res (2007) 9(1):R6. doi: 10.1186/bcr1639 - DOI - PMC - PubMed
    1. Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, et al. . Annual Report to the Nation on the Status of Cance -2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State. J Natl Cancer Inst (2015) 107(6):djv048. doi: 10.1093/jnci/djv048 - DOI - PMC - PubMed
    1. Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, et al. . Residual Risk of Breast Cancer Recurrence 5 Years After Adjuvant Therapy. J Natl Cancer Inst (2008) 100(16):1179–83. doi: 10.1093/jnci/djn233 - DOI - PMC - PubMed
    1. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. . 20-Year Risks of Breast-Cancer Recurrence After Stopping Endocrine Therapy at 5 Years. N Engl J Med (2017) 377(19):1836–46. doi: 10.1056/NEJMoa1701830 - DOI - PMC - PubMed
    1. van Maaren MC, de Munck L, Strobbe LJA, Sonke GS, Westenend PJ, Smidt ML, et al. . Ten-Year Recurrence Rates for Breast Cancer Subtypes in the Netherlands: A Large Population-Based Study. Int J Cancer (2019) 144(2):263–72. doi: 10.1002/ijc.31914 - DOI - PubMed